文献速递显微修复重建创面修复

生物活性显微外科与CCL2:周围神经修复免疫调控策略综述

Bioactive Microsurgery and CCL2: A Narrative Review of Immune Modulation Strategies for Peripheral Nerve Repair.
PubMed 文献 · Ann Plast Surg · 2026-09-04

本文为叙述性综述,评估以CCL2(单核细胞趋化蛋白-1,MCP-1)作为周围神经显微外科生物活性辅助手段的科学依据、临床前证据与转化策略。多项临床前损伤模型显示,CCL2可增强巨噬细胞驱动的修复、促进血管生成、支持施旺细胞活性并加速轴突再生;缺失CCL2信号损害功能恢复,而在早期再生窗口靶向递送可改善结局且无持续炎症证据。水凝胶、微缝线与间充质基质细胞疗法被认为是可行的递送平台。

要点

  • CCL2调控巨噬细胞募集与极化,是神经免疫修复的关键调节因子
  • 早期再生窗口靶向递送CCL2可改善恢复,且未见持续炎症
  • 水凝胶、微缝线及间充质基质细胞是可行的术中递送平台

核心结论

  • 临床前数据支持术中调控CCL2作为将免疫生物学与显微外科技术整合的新策略,有望改善再生与移植物整合,并通过精确的时空控制降低神经病理性疼痛风险。

研究设计与样本

  • 叙述性综述,综合周围神经损伤模型中涉及CCL2的临床前研究,包括基因敲除与过表达系统、移植物整合、干细胞治疗及疼痛调控,并关注适用于术中场景的递送方式。

主要发现

  • 在多种临床前损伤模型中,CCL2可增强巨噬细胞驱动的修复、促进血管生成、支持施旺细胞活性并加速轴突再生。
  • 缺失CCL2信号会损害功能恢复,而在早期再生窗口靶向递送可改善结局,且无持续炎症证据。
  • 水凝胶、微缝线与间充质基质细胞疗法被支持为CCL2递送的可行平台。

临床怎么用

  • 可将CCL2调控定位为周围神经显微修复的术中生物活性辅助策略,重点在早期再生窗口通过水凝胶、微缝线或细胞载体实现局部递送。

局限性

  • 证据来自临床前研究,尚缺乏临床数据;作为叙述性综述,未报告系统检索与定量合并方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral nerve injuries often result in incomplete functional recovery, despite technically successful microsurgical repair. Traditional strategies focus on structural continuity but neglect the immunobiological environment critical for regeneration. CCL2 (monocyte chemoattractant protein-1, MCP-1), a chemokine that coordinates macrophage recruitment and polarization, has emerged as a key regulator of neuroimmune responses involved in nerve healing. This narrative review evaluates the scientific rationale, preclinical evidence, and translational strategies for using CCL2 as a bioactive adjunct in peripheral nerve microsurgery. We synthesize findings from preclinical studies involving CCL2 in nerve injury models, including knockout and overexpression systems, graft integration, stem cell-based therapies, and pain modulation, with emphasis on delivery mechanisms applicable to intraoperative settings such as hydrogels, microsutures, and cellular approaches. Across multiple preclinical injury models, CCL2 has been shown to enhance macrophage-driven repair, promote angiogenesis, facilitate Schwann cell activity, and accelerate axonal regrowth. Loss of CCL2 signaling impairs functional recovery, whereas targeted delivery during the early regenerative window improves outcomes without evidence of prolonged inflammation. These studies further support hydrogels, microsutures, and mesenchymal stromal cell-based therapies as feasible platforms for CCL2 delivery. Together, these data support intraoperative CCL2 modulation as a novel, mechanistically grounded strategy to integrate immune biology with microsurgical technique. This bioactive approach has the potential to improve regeneration and graft integration while minimizing the risk of neuropathic pain through precise temporal and anatomic control of CCL2 delivery.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Sarpong C, Khoury S, Bangayan K, et al. Bioactive Microsurgery and CCL2: A Narrative Review of Immune Modulation Strategies for Peripheral Nerve Repair. Ann Plast Surg. 2026. PMID: 42696662. doi:10.1097/SAP.0000000000004888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。